SEP 19, 2016 12:13 PM PDT

Plague Toxin Treats Common Autoimmune Disease

WRITTEN BY: Kara Marker
Yersinia pestis, the bacterial species responsible for numerous and deadly outbreaks of plague throughout human history, contains a toxin that might actually be beneficial to human health. 
Yersinia pestis bacteria | Credit: abc13.com
The same bacterial toxin that caused the 15th century “Black Death” epidemic of bubonic plague by invading host cells and disrupting valuable signaling responses to promote pathogenesis could be used to treat a common inherited autoimmune disease called Familial Mediterranean Fever (FMF). The autoinflammatory condition affects 1 in 200 to 1 in 1000 people in populations originating from the Mediterranean region, namely those with Armenian, Arab, Turkish, or Jewish ancestry.

Individuals with FMF have recurring episodes of painful inflammation in the abdomen, chest, or joints often accompanied by fever, rash, and headache, with initial episodes usually occurring during childhood or the teenage years. Episodes can be as short as 12 hours and as long as three days.

Lack of proper intervention in patients with FMF can lead to organ failure due to amyloidosis, the buildup of protein deposits in the body’s organs and tissues. FMF is passed down through generations in an autosomal dominant pattern, meaning it’s possible for a child to inherit the disease from just one affected parent.

The symptoms of FMF stem from mutations in a gene called MEFV, which is responsible for making a protein called pyrin, found in leukocytes. Pyrin is a regulator of inflammation, and when MEFV mutations inhibit ample production of pyrin, the inflammatory process can grow largely out of control.

Lead author of the recent Cell Host & Microbe study James Bliska, PhD., said the findings “may explain the natural selection process behind a chronic condition that affects a high prevalence of people originating around the Mediterranean Sea.” Bliska is a Professor in the Department of Molecular Genetics & Microbiology at Stony Brook University School of Medicine.

Bliska and his team researched the Y. pestis toxin, also found in bacterial species Y. pseudotuberculosis, because of its ability to recruit human kinases PRK1 and PRK2 to phosphorylate pyrin and subsequently restrict its inflammasome from causing an over-the-top autoimmune response from FMF-related MEFV mutations. 

So-called Yersinia outer proteins (Yops) promote pathogenesis by disrupting host signaling responses that control the immune response to bacterial infections. Miraculously, the same disruption that caused multiple epidemics and taking hundreds of thousands of lives could also be able to treat a common autoimmune disease with no known cure. 

Bliska and his team will continue to unravel the relationship between Yops and the control of FMF, encouraged by the increasing potential for drug developers to create new therapies that mimic this method of immune inhibition. 
 


Sources: Stony Brook University, Blood Journal, Genetics Home Reference
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 19, 2021
Cell & Molecular Biology
Mouse Fathers Passed Immunity Onto Offpsring After Infection
OCT 19, 2021
Mouse Fathers Passed Immunity Onto Offpsring After Infection
Parents pass their genes on to their children. But they can pass down other things too with epigenetic marks, chemical t ...
NOV 17, 2021
Health & Medicine
Nutrients for Reducing Autoimmune Disease Risk
NOV 17, 2021
Nutrients for Reducing Autoimmune Disease Risk
Want to reduce your chances of having your immune system turn on your body and start destroying your perfect health? Loo ...
DEC 06, 2021
Microbiology
Sino Biological Launched Omicron Variant Research Reagents
DEC 06, 2021
Sino Biological Launched Omicron Variant Research Reagents
Sino Biological Newly Launched A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529) Beijing, China, D ...
DEC 30, 2021
Clinical & Molecular DX
Treating Rheumatoid Arthritis: No More Trial and Error?
DEC 30, 2021
Treating Rheumatoid Arthritis: No More Trial and Error?
  Treating rheumatoid arthritis can be like throwing darts—doctors don’t always hit the bullseye. Trial ...
JAN 13, 2022
Immunology
Convalescent Plasma Therapy 'Keeps up' With COVID Variants
JAN 13, 2022
Convalescent Plasma Therapy 'Keeps up' With COVID Variants
A recent study has demonstrated that COVID-19 convalescent plasma treatment (or blood from individuals who have recovere ...
JAN 18, 2022
Drug Discovery & Development
Identifying Oncostatin M (OSM): One Protein's Role in Severe Asthma
JAN 18, 2022
Identifying Oncostatin M (OSM): One Protein's Role in Severe Asthma
Asthma is a chronic condition that is characterized by difficulty breathing, coughing, and wheezing which is caused, in ...
Loading Comments...